Dr. Richard Chin

• 
  biz.yahoo.com/bw/081030/20081030006624.html?.v=2 - [Cached Version]
  Published on: 10/31/2008    Last Visited: 10/31/2008  

  Richard Chin, M.D., Former President and CEO of OXiGENE, Named CEO of Non-Profit Pharmaceutical Company
  
  SAN FRANCISCO & NEW DELHI--(BUSINESS WIRE)--The Institute for OneWorld Health, the US-based non-profit pharmaceutical company that develops drugs for people with neglected infectious diseases in the developing world, today announced the appointment of Richard Chin, M.D., as its new Chief Executive Officer.
  
  "We are excited to bring a scientist of Dr. Chin's caliber to lead OneWorld Health into its next phase of growth and development," said Herbert Montgomery, Board member and Co-Chair of OneWorld Health's Search Committee of the Board of Directors.
  ...
  "I am delighted to join OneWorld Health and I look forward to working with its leadership, partners and supporters to develop safe, effective and affordable drugs for the world's most impoverished patients," said Dr. Chin. "I've long admired OneWorld Health's groundbreaking, compelling approach toward addressing global health challenges and I look forward to helping advance their mission."
  
  Dr. Chin is a Harvard trained, Board Certified Internist, with extensive expertise in drug development. Dr. Chin has overseen over 40 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eight New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a major textbook on clinical trial medicine. Dr. Chin joins OneWorld Health from OXiGENE, where he served as President and Chief Executive Officer. Prior to OXiGENE, Dr. Chin served as Senior Vice President and Head of Global Development for Elan Corporation, where he had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director.
  
  Dr. Chin holds a Medical Degree from Harvard Medical School, received a Masters degree and Bachelor of Arts degree in Law with honors from Oxford University in England under a Rhodes Scholarship and graduated with a Bachelor of Arts in Biology, magna cum laude, from Harvard University. Dr. Chin is a Diplomate, American Board of Internal Medicine and is licensed to practice medicine in California. He previously served on the Adjunct Clinical Faculty of Stanford University School of Medicine and currently serves on the Board of Directors of Genmedica, located in Barcelona, Spain.
  
  Dr. Chin succeeds Ahvie Herskowitz, M.D., co-Founder and current CEO.

• 
  www.corporate-ir.net/ireye/ir_site.zhtml?ticker=OXGN&sc - [Cached Version]
  Published on: 9/12/2006    Last Visited: 10/26/2008  

  "Having developed one of the leading current therapies for AMD during my tenure at Genentech, I am well aware of the advantages of better administration options in this disease state" commented Richard Chin, M.D., President and Chief Executive Officer. "We believe pursuing an indication in AMD for CA4P is the right strategy for patients provided we see maintenance of vision in a similar range as current antiangiogenic agents and CA4P continues to demonstrate an acceptable safety profile" Dr. Chin continued. "Our goal in ophthalmology, as in oncology, is to deploy our resources thoughtfully toward meeting the greatest unmet medical need."
  
  The Company also announced the closure of enrollment of its Phase II CA4P clinical trial in myopic macular degeneration (MMD-213), with 22 of the previously planned 36 patients enrolled to date. The last of the enrolled patients are expected to complete the MMD trial by the end of the year. This trial was designed to evaluate the safety and efficacy of three dose groups (27, 36, and 45 mg/m2) of CA4P for the treatment of subfoveal choroidal neovascularization (CNV) in subjects with pathologic myopia. "We are satisfied with the results of the trial to date and believe that we will have enough data from the trial to now focus our ophthalmology efforts on more effective methods of administration for AMD," added Dr. Chin.

• 
  www.corporate-ir.net/ireye/ir_site.zhtml?ticker=OXGN&sc - [Cached Version]
  Published on: 2/12/2008    Last Visited: 10/26/2008  

  WALTHAM, Mass., Feb 05, 2008 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that President and CEO Richard Chin, M.D., will present a corporate overview and update at the BIO CEO and Investor Conference on Tuesday, February 12, at 10:15 a.m. EST (7:15 a.m. PST), in the Waldorf-Astoria hotel's Norse Suite in New York City, NY.

• 
  www.crmz.com/Report/ReportPreview.asp?BusinessId=15092 - [Cached Version]
  Published on: 6/15/2008    Last Visited: 6/15/2008  

  Richard Chin
  President, Chief Executive Officer, Director
  OXiGENE, Inc.

• 
  www.iowh.org/media/index.php?PHPSESSID=bc23d50222637be6 - [Cached Version]
  Last Visited: 11/14/2008  

  SAN FRANCISCO, USA AND NEW DELHI, INDIA - October 30, 2008 - The Institute for OneWorld Health, the US-based non-profit pharmaceutical company that develops drugs for people with neglected infectious diseases in the developing world, today announced the appointment of Richard Chin, M.D., as its new Chief Executive Officer.
  
  Read more >

• 
  birmingham.bizjournals.com/birmingham/othercities/sanfr - [Cached Version]
  Published on: 11/28/2008    Last Visited: 12/2/2008  

  What goes around comes around for Dr. Richard Chin.
  
  Growing up in the underdeveloped Korea of the 1970s, Chin was vaccinated against smallpox by the World Health Organization. Now he is the new CEO at the Institute for OneWorld Health, a San Francisco nonprofit drug-development company aimed at deeply embedded diseases in some of the world's poorest countries.
  
  "It was a no-brainer," Chin recalled about his response to a recruiter's call.
  
  He started on the job in late October.
  
  But after a handful of biotech stints — including chief executive of East Coast cancer and eye drug developer Oxigene Inc. and head of biotherapeutics clinical research at Genentech Inc. — Chin may face his toughest assignment.
  ...
  "In our case," Chin said, "ROI doesn't change even if the market changes."
  ...
  Under Chin, the institute could make an even deeper impact.
  
  Among its preclinical programs are treatments for diarrheal diseases, which in developing countries kill about 2 million children a year, and soil-transmitted helminthiasis, a group of parasitic intestinal infections, including hookworm, whose 2 billion victims with active infections, according to the World Health Organization, mostly are school-age children.
  
  The institute inked a deal this spring that gives it unprecedented access to about 800,000 compounds in the library of pharmaceutical giant Roche. No money exchanged hands in the deal, but the institute is funding the screening program.
  
  "There are probably opportunities to do that on a bigger scale," Chin said.

• 
  sanfrancisco.bizjournals.com/sanfrancisco/related_conte - [Cached Version]
  Published on: 7/15/2009    Last Visited: 8/7/2009  

  ...CEO, Dr. Richard Chin, stepped down in October and now heads the Institute for OneWorld Health, a nonprofit drug developer in San Francisco

• 
  www.sec.gov/Archives/edgar/data/1337252/0001181431-05-0 - [Cached Version]
  Published on: 8/30/2005    Last Visited: 3/30/2006  

  0001337252 Chin Richard 230 THIRD AVENUE WALTHAM, MA 02451 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/908259/0001181431-08-00 - [Cached Version]
  Published on: 1/15/2008    Last Visited: 1/17/2008  

  0001337252 Chin Richard 230 THIRD AVENUE WALTHAM MA 02451 1 1 0 0 President and CEO

Page:  1 2 3 4 5